Amarin Corporation plc
NASDAQ:AMRN · NASDAQ Global Market
+$0.29 today
Vol 0.09M · Avg 0.07M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:AMRN · Revenue to Net Income
Key Ratios
Analysis
$214.9M of revenue converted into -$33.6M of net income for the selected period. Gross margin is 50.2% and net margin is -15.4%, showing how much revenue survives after costs and taxes. EPS is $-1.62, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $213.6M -6.5% | $228.6M -25.5% | $306.9M -16.9% | $369.2M -36.7% | $583.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $92.8M -37.0% | $147.2M +4.1% | $141.4M +11.6% | $126.7M +4.4% | $121.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $120.9M +48.5% | $81.4M -50.8% | $165.5M -31.7% | $242.5M -47.5% | $461.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 56.6% +21.0pp | 35.6% -18.3pp | 53.9% -11.7pp | 65.7% -13.5pp | 79.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $19.8M -5.1% | $20.9M -6.1% | $22.2M -26.9% | $30.4M +3.8% | $29.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $115.0M -24.5% | $152.3M -23.8% | $199.9M -34.3% | $304.4M -25.4% | $408.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $134.8M -22.2% | $173.2M -22.0% | $222.2M -36.2% | $348.4M -22.8% | $451.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.0M +0.5% | $3.0M +1.7% | $3.0M -4.2% | $3.1M +8.4% | $2.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$33.0M +55.5% | -$74.2M -46.3% | -$50.7M +49.7% | -$100.7M -805.4% | $14.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -15.5% +17.0pp | -32.4% -15.9pp | -16.5% +10.8pp | -27.3% -29.7pp | 2.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$13.9M +84.8% | -$91.8M -62.1% | -$56.6M +46.5% | -$105.9M -1108.1% | $10.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -6.5% +33.6pp | -40.2% -21.7pp | -18.4% +10.2pp | -28.7% -30.5pp | 1.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $10.9M -19.0% | $13.4M +13.0% | $11.9M +320.8% | $2.8M +131.1% | $1.2M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $7.0K +0.0% | $7.0K -12.5% | $8.0K -46.7% | $15.0K -88.4% | $129.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$22.1M -251.4% | $14.6M +395.5% | $2.9M +42.7% | $2.1M +161.6% | $789.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$36.0M +53.3% | -$77.2M -43.8% | -$53.7M +48.3% | -$103.8M -1019.4% | $11.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -16.9% +16.9pp | -33.8% -16.3pp | -17.5% +10.6pp | -28.1% -30.1pp | 1.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $2.8M -44.8% | $5.0M -8.4% | $5.4M +172.4% | $2.0M -43.9% | $3.6M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$38.8M +52.8% | -$82.2M -39.0% | -$59.1M +44.1% | -$105.8M -1468.9% | $7.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -18.2% +17.8pp | -35.9% -16.7pp | -19.3% +9.4pp | -28.7% -30.0pp | 1.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +55.0% | -$4 -33.3% | -$3 +42.3% | -$5 -1433.3% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +55.0% | -$4 -33.3% | -$3 +42.3% | -$5 -1468.4% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $20.7M +1.0% | $20.5M +4.3% | $19.7M -1.8% | $20.1M +1.3% | $19.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $20.7M +1.0% | $20.5M +0.8% | $20.4M +1.6% | $20.1M -0.3% | $20.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alto Neuroscience, Inc.
NYSE:ANRO
$782.59M
DBV Technologies S.A.
NASDAQ:DBVT
$378.32M
Silence Therapeutics plc
NASDAQ:SLN
$326.39M
Cellectis S.A.
NASDAQ:CLLS
$307.28M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$305.94M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$293.31M
AC Immune S.A.
NASDAQ:ACIU
$241.41M
Altimmune, Inc.
NASDAQ:ALT
$238.81M
Korro Bio, Inc.
NASDAQ:KRRO
$128.50M
enGene Holdings Inc.
NASDAQ:ENGN
$88.57M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AMRN generate?
Amarin Corporation plc (AMRN) reported $213.65M of revenue in fiscal 2025.
Is AMRN profitable?
Amarin Corporation plc (AMRN) reported -$38,798,000.00 of net income, with a net margin of -18.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.